As of May 18
| +0.09 / +5.36%|
The 1 analysts offering 12-month price forecasts for MabVax Therapeutics Holdings Inc have a median target of 54.00, with a high estimate of 54.00 and a low estimate of 54.00. The median estimate represents a +2,950.85% increase from the last price of 1.77.
There are no recommendations available.
Move your mouse over a quarter or year to see how estimates have changed over time.